PEARL研究:哌柏西利联合内分泌治疗对比卡培他滨在AI耐药HR+/HER2-转移性乳腺癌的III期试验
PEARL是一项多中心III期随机研究,纳入芳香化酶抑制剂(AI)耐药的HR+/HER2-转移性乳腺癌患者,分为两个连续队列,分别比较哌柏西利联合依西美坦或氟维司群与卡培他滨的疗效。主要终点为队列2和ESR1野生型患者的无进展生存期(PFS),结果显示哌柏西利联合内分泌治疗在PFS上未优于卡培他滨,但安全性和生活质量更优。
要点
- 哌柏西利联合内分泌治疗在AI耐药HR+/HER2-转移性乳腺癌中PFS未优于卡培他滨。
- 哌柏西利联合内分泌治疗安全性更好,3-4级中性粒细胞减少常见但手足综合征和腹泻较少。
- 哌柏西利联合内分泌治疗显著改善生活质量,全球健康状况恶化时间HR为0.67。
核心结论
- 在AI耐药的HR+/HER2-转移性乳腺癌患者中,哌柏西利联合内分泌治疗相比卡培他滨未显示PFS的统计学优效性。
研究设计与样本
- 多中心、III期随机对照试验(PEARL),纳入AI耐药转移性乳腺癌患者,队列1随机分配至哌柏西利+依西美坦或卡培他滨,队列2随机分配至哌柏西利+氟维司群或卡培他滨。
- 队列1纳入296例患者,队列2纳入305例患者,随机比例1:1,分层因素包括疾病部位、既往内分泌治疗敏感性、既往转移性化疗和来源国家。
- 共同主要终点为队列2和ESR1野生型患者(队列1+队列2)的PFS,基线循环肿瘤DNA分析ESR1热点突变。
主要发现
- 队列2中位PFS:哌柏西利联合内分泌治疗7.5个月 vs 卡培他滨10.0个月,调整HR 1.13(95%CI 0.85-1.50)。
- ESR1野生型患者中位PFS:哌柏西利联合内分泌治疗8.0个月 vs 卡培他滨10.6个月,调整HR 1.11(95%CI 0.87-1.41)。
- 哌柏西利+依西美坦、哌柏西利+氟维司群和卡培他滨组最常见的3-4级毒性分别为中性粒细胞减少(57.4%、55.7%和5.5%)、手足综合征(0%、0%和23.5%)和腹泻(1.3%、1.3%和7.6%)。
- 哌柏西利联合内分泌治疗改善生活质量,全球健康状况恶化时间调整HR 0.67(95%CI 0.53-0.85)。
临床怎么用
- 对于AI耐药的HR+/HER2-转移性乳腺癌,哌柏西利联合内分泌治疗未在PFS上优于卡培他滨,但可作为考虑生活质量和安全性的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not been compared with that of chemotherapy in a phase III trial. PATIENTS AND METHODS: PEARL is a multicentre, phase III randomised study in which patients with aromatase inhibitor (AI)-resistant MBC were included in two consecutive cohorts. In cohort 1, patients were randomised 1 : 1 to palbociclib plus exemestane or capecitabine. On discovering new evidence about estrogen receptor-1 (ESR1) mutations inducing resistance to AIs, the trial was amended to include cohort 2, in which patients were randomised 1 : 1 between palbociclib plus fulvestrant and capecitabine. The stratification criteria were disease site, prior sensitivity to ET, prior chemotherapy for MBC, and country of origin. Co-primary endpoints were progression-free survival (PFS) in cohort 2 and in wild-type ESR1 patients (cohort 1 + cohort 2). ESR1 hotspot mutations were analysed in baseline circulating tumour DNA. RESULTS: From March 2014 to July 2018, 296 and 305 patients were included in cohort 1 and cohort 2, respectively. Palbociclib plus ET was not superior to capecitabine in both cohort 2 [median PFS: 7.5 versus 10.0 months; adjusted hazard ratio (aHR): 1.13; 95% confidence interval (CI): 0.85-1.50] and wild-type ESR1 patients (median PFS: 8.0 versus 10.6 months; aHR: 1.11; 95% CI: 0.87-1.41). The most frequent grade 3-4 toxicities with palbociclib plus exemestane, palbociclib plus fulvestrant and capecitabine, respectively, were neutropenia (57.4%, 55.7% and 5.5%), hand/foot syndrome (0%, 0% and 23.5%), and diarrhoea (1.3%, 1.3% and 7.6%). Palbociclib plus ET offered better quality of life (aHR for time to deterioration of global health status: 0.67; 95% CI: 0.53-0.85). CONCLUSIONS: There was no statistical superiority of palbociclib plus ET over capecitabine with respect to PFS in MBC patients resistant to AIs. Palbociclib plus ET showed a better safety profile and improved quality of life.
引用
- Martin M, Zielinski C, Ruiz-Borrego M, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL. Ann Oncol. 2020. PMID: 33385521. doi:10.1016/j.annonc.2020.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。